Some of the first U.S. post-approval uses of the two new systems for renal denervation were performed at Cleveland Clinic. The specialists involved share what’s essential to know about the new technology.
Read MorePericardial CO2 Insufflation via Intentional Coronary Vein Perforation Facilitates Epicardial Access
CO2 insufflation of the pericardial cavity is emerging as an important method to safely achieve pericardial access for epicardial mapping and catheter ablation for ventricular tachycardia.
The Two FDA-Approved M-TEER Systems Are Comparable at 1-Year Follow-Up, CLASP IID Data Show
Noninferiority of the PASCAL device relative to MitraClip extends through at least one year, and a substudy finds good outcomes with PASCAL in patients with complex anatomy.
Patient-Reported Outcomes Improved With Myectomy for Obstructive HCM
At 12 months after septal myectomy, patients in Cleveland Clinic’s SPIRIT-HCM study had significant improvement in quality-of-life measures despite lack of correlation with physician assessment.
Program Offers Lifelong Congenital Heart Disease Care
Surgeons discuss the current paradigm for adult congenital heart disease surgery and outline recommendations to strengthen the subspecialty.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Semaglutide Shows Secondary Cardiovascular Prevention Benefits in Patients Without Diabetes
For the first time, a pharmacotherapy for overweight and obesity has reduced cardiovascular events in patients with established cardiovascular disease in the absence of type 2 diabetes.
Vital Statistics in Adult Cardiac Surgery, Ischemic Heart Disease and Vascular Disease (Infographic)
Interested in our latest outcomes and volumes in these three key areas? Check out this infographic-style recap.
Study Strongly Links Sleep-Related Hypoxia Metrics With Incident Atrial Fibrillation
Findings in a large patient sample implicate sleep-related hypoxia as an important biological pathway of atrial fibrillation and a clinically relevant driver of risk for the condition.
Novel siRNA Reduces Lipoprotein(a) by More Than 90% for 48 Weeks
A phase 1 study finds that lepodisiran can essentially eliminate Lp(a) from the circulation long enough to potentially allow once- or twice-yearly dosing. Phase 2 testing is now underway.
TRILUMINATE Health Status Analysis: T-TEER Patients Likelier to Be ‘Alive and Well’ at 1 Year
A secondary analysis of the pivotal trial for tricuspid transcatheter edge-to-edge repair indicates that it yields clinically meaningful benefit for select patients with isolated severe tricuspid regurgitation.
TAVR and SAVR Perform Similarly at 5 Years in Low-Risk Patients, PARTNER 3 Report Shows
Five-year results from the landmark trial show outcomes converging since year 1, with statistically comparable results on the primary endpoints and similar rates of valve failure.